Faculty


Mark W. Geraci, M.D.
Professor of Medicine

EDUCATION/TRAINING

University of Colorado, Boulder, CO
1983B.A.Molecular Biology

Johns Hopkins University School of Medicine, Baltimore, MD
1987M.D.


UCD
4200 E. Ninth Ave.
Denver, CO 80262
Tel: 303.315.7507
Mark.Geraci@uchsc.edu

PROFESSIONAL EXPERIENCE

1987-1988
Medical Internship, Massachusetts General Hospital, Harvard Medical School, Boston, MA

1988-1990
Medical Residency, Massachusetts General Hospital, Harvard Medical School, Boston, MA

1990-1993
Fellow, University of Colorado Denver, Denver, CO

1993-1994
Instructor / Fellow, University of Colorado Denver, Denver, CO

1994-Pres.
Assistant Professor, Department of Medicine, University of Colorado Denver, Denver, CO.

1996-Pres.
Medical Director, Inpatient Pulmonary Services, University of Colorado Denver, Denver, CO.

1999-Pres.
Director, Gene Expression Core Facility, University of Colorado Denver, Denver, CO.

2001-2005
Associate Professor, Department of Medicine, University of Colorado Denver, Denver, CO.

2005-Pres.
Professor, Department of Medicine, University of Colorado Denver, Denver, CO.

2001-Pres.
Assistant Chief of Medicine, Department of Medicine, University of Colorado Denver, Denver, CO.

HONORS

1982 Alpha Epsilon Delta, Premedical Honor Society
1983 Phi Beta Kappa, Academic Honor Society
1983 Graduate with Distinction, University of Colorado
1986 Lange Publications medical Excellence Award
1987 Alpha Omega Alpha, Medical Honor Society
1992 American Federation of Clinical Research National Trainee Investigator Award
1992-1993 Allen and Hanbury’s Respiratory Institute Pulmonary Fellowship Award
1993-1994 American Heart Association of Colorado Research Fellowship
1994-1999 NHLBI K08 Clinical Investigator Development Award
2000-Pres Ad Hoc Member, NHLBI Peer Review

SELECTED PEER-REVIEWED PUBLICATIONS

  1. Case records of the Massachusetts General Hospital (Case 12-1989). New England Journal of Medicine 320:790-799, 1989.
  2. Geraci, M.W., Miller, Y.E., Escobedo-Morse, A., and Kane,M.A. Novel bombesin-like peptide binding proteins from lung. American Journal of Respiratory Cell and Molecular Biology 10: 331-338, 1994.
  3. Geraci, M., D. Shepherd, M. Moore, J. Vernon, J. Allard, J. Shannon, and N.F. Voelkel. Rat prostacyclin synthase: Cloning and regulation of gene expression in the lung. Chest 111 (6Suppl):129S, 1997.
  4. Geraci, M., B. Gao, D. Shepherd, J. Allard, D. Curiel, J. Westcott, and N. Voelkel. Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice. Chest 114 (1Suppl):99S, 1998.
  5. Voelkel, N.F., Cool, C., Lee, S.D., Wright, L., Geraci, M.W., and Tuder, R.M. Primary pulmonary hypertension: Between inflammation and cancer. Chest 114: 225S-230S, 1998.
  6. Girod, C.E., D.H. Shin, M.W. Geraci, H.B. Warren, L.G. Dobbs, B. Gao, J.S. Rainer, A.K. Bauer, M. Ikegami, J.M. Shannon, and Y.E. Miller. Surfactant protein C promoter-driven expression of T1-alpha induces lung inflammation. Chest 116 (1Suppl):61S, 1999.
  7. Tuder, R.M., Wang, J., Cool, C.D., Wright, L., Geraci, M.W., Badesch, D. B. and Voelkel, N.F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159:1925-1932, 1999.
  8. Geraci, M.W., Gao, B., Shepherd, D.C., Moore, M.D., Westcott, J.Y., Alger, L.A., Tuder, R.M., and Voelkel, N.F. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of hypoxic pulmonary hypertension. J. Clin. Invest. 103:1509-1515, 1999.
  9. Gupta,R.A., Tan, J., Krause, W.F., Geraci, M.W., Willson, T.M., Dey, S.K., and DuBois, R.N. Prostacyclin-mediated activation of PPARd in colorectal cancer. Proc. Nat. Acad. Sciences, 97:13275-13280, 2000.
  10. Malkinson AM, Bauer A, Brown A, Dwyer-Nield L, Koski K, Keith RL, Geraci MW, Miller YE. Experimental Evidence from an Animal Model of Adenocarcinoma that Chronic Inflammation Enhances Lung Cancer Risk. Chest. 117(5 Suppl 1):228S, 2000.
  11. Golpon,H.A., Geraci, M.W. , Moore,M.D., Miller,H.L., Miller,G.J., Tuder,R.M., and Voelkel,N.F. Hox genes in human lung: Altered expression in primary pulmonary hypertension and emphysema. American Journal of Pathology 158:955-966, 2001.
  12. Geraci, M.W., Moore, M.D., Gessel, T.L., Yeager, M.E., Alger, L., Golpon, H., Gao, B., Loyd, J.E., Tuder, R.M., and Voelkel, N.F. Gene expression patterns in the lungs of patients with primary pulmonary hypertension – A gene microarray analysis. Circulation Research, 88:555-562, 2001.
  13. Geraci, M.W., Gao, B., Hoshikawa, Y., Yeager, M.E., Tuder, R.M., and Voelkel, N.F. Genomic approaches to research in pulmonary hypertension. Respiratory Research, http://respiratory-research.com/REVIEWS/rr-2-4-210.pdf May, 2001.
  14. Hoshikawa, Y., Voelkel, N.F., Gesell, T.L., Moore, M.D., Morris, K.G., Alger, L.A., Narumiya, S., and Geraci, M.W. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. American Journal of Respiratory and Critical Care Medicine 2001 Jul;164(2):314-318, 2001.
  15. Parker, T.A., Afshar, S., Kinsella, J.P., Grover, T.R., Gebb, S. Geraci, M., Shaul, P.W., and Abman, S.H. Effects of chronic estrogen receptor blockade on ovine perinatal pulmonary circulation. Am J Physiol Heart Circ Physiol, 281(3):H1005-14, 2001.
  16. Tuder,R.M., Yeager,M.E., Geraci,M., Golpon,H.A., and Voelkel,N.F. Severe pulmonary hypertension after the discovery of the familial PPH gene. European Respiratory Journal, Jun;17(6): 1065-9, 2001.
  17. Tuder, R.M., Chacon, M., Alger, L., Wang, J., Taraseviciene-Stewart, L., Kasahara, Y., Cool, C.D., Bishop, A.E., Geraci, M., Semenza, G. L., , Yacoub, M., Polak, J.M., andVoelkel, N.F. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J. Pathol: 195:367-374, 2001.
  18. Spalding, A.C., Jotte, R.M., Scheinman, R.I. Geraci, M.W., and Johnson, G.L. TRAIL and inhibitors of apoptosis are opposing determinants for NFkB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene, In Press, 2002.
  19. Keith, R.L., Miller, Y.E., Gesell, T.L., Moore, M.D. Malkinson, A.M., and Geraci, M.W. Pulmonary prostacyclin synthase overexpression improves survival following butylated hydroxytoluene exposure. Proceedings of Advances in Prostaglandin and Leukotriene Research, In Press, 2002.
  20. Keith, R.L., Miller, Y.E., Hoshikawa, Y., Malkinson, A.M., Moore, M.D., and Geraci, M.W. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Research, In Press, 2002.
  21. Hoshikawa, Y., Geraci, M.W., and Voelkel, N.F. Prostacyclin receptor (PGI-R) and synthase (PGI-S) gene expression in heart and lungs are altered during hypoxia. Submitted.